Tibsovo FDA Approval History
FDA Approved: Yes (First approved July 20, 2018)
Brand name: Tibsovo
Generic name: ivosidenib
Dosage form: Tablets
Company: Agios Pharmaceuticals, Inc.
Treatment for: Acute Myeloid Leukemia
Tibsovo (ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor for the treatment of patients with acute myeloid leukemia who have an IDH1 mutation.
Development Timeline for Tibsovo
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.